Skip to content
Meeting on the Mesa Roundtable Part 2:  Applying "A-Cell" Concepts when Developing Cell Therapies episode artwork

Oct 27, 2022 24 min

Meeting on the Mesa Roundtable Part 2: Applying "A-Cell" Concepts when Developing Cell Therapies

from Rx for Biotech Hosted by Podcast Host Christopher Leidli

There are many hurdles to streamlined, cost-effective manufacturing of cell and gene therapy products. To help address this, the Alliance for Regenerative Medicine published A-Cell, a case-based guidebook to help drug developers incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs. A-Cell builds on previous QbD efforts that were applied to the manufacturing of monoclonal antibodies (A-Mab), vaccines (A-Vax), and more recently, gene therapies (A-Gene), bringing best practices in CMC to a case study of a CAR-T therapy manufacturing. This is the second of a two-part deep dive into the A-Cell document as part of a round table conducted during Meeting on the Mesa. This episode covers key questions around conducting a risk assessment and best practices for product and process characterization for cell therapies.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Meeting on the Mesa Roundtable Part 2: Applying "A-Cell" Concepts when Developing Cell Therapies

0:00 24:07

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Rx for Biotech?

This episode is 24 minutes long.

When was this Rx for Biotech episode published?

This episode was published on October 27, 2022.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.